Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 4Genitourinary 3Thoracic 2Gynecologic 2Gastrointestinal 2Dermatologic 2Tumor-Agnostic 1Other solid neoplasm 1Lymphoid 1Breast 1

Conditions

Melanoma 38Carcinoma, Renal Cell 12Carcinoma, Non-Small-Cell Lung 12Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 8Carcinoma, Merkel Cell 8Uterine Cervical Neoplasms 7Stomach Neoplasms 7Colorectal Neoplasms 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Small Cell Lung Carcinoma 5Neoplasms 5Kidney Neoplasms 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Esophageal Neoplasms 3Breast Neoplasms 3Urogenital Neoplasms 2Skin Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Neoplasms by Histologic Type 2Microsatellite Instability 2Mesothelioma, Malignant 2Mesothelioma 2Lymphoma 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Squamous Cell 2

Interventions

pembrolizumab 9Nivolumab 4Fluorouracil 4Mohs Surgery 3talimogene laherparepvec 2atezolizumab 2Therapeutics 2Photochemotherapy 2Petrolatum 2Paclitaxel 2Niacinamide 2Aminolevulinic Acid 2tozuleristide 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1selinexor 1regorafenib 1peginterferon alfa-2b 1peginterferon alfa-2a 1osimertinib 1nanocis 1methyl 5-aminolevulinate 1fludarabine 1daromun 1cobimetinib 1cemiplimab 1avelumab 1aldesleukin 1aflibercept 1afamelanotide 1Vitamin D 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × atezolizumab × Dermatologic × Clear all
NCT06444815 2026-04-07

STEALTH-001

KaliVir Immunotherapeutics

Phase 1 Recruiting
60 enrolled
DermatologicGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Mesothelioma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡